|
|
Blood, 15 November 2003, Vol. 102, No. 10, pp. 3615-3620.
Prepublished online as a Blood First Edition Paper on July 17, 2003; DOI 10.1182/blood-2003-05-1369.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A
Mikael Tranholm,
Kim Kristensen,
Annemarie T. Kristensen,
Charles Pyke,
Rasmus Røjkjær, and
Egon Persson
From Novo Nordisk A/S, Måløv, Denmark, The Royal Veterinary and Agricultural University, Copenhagen, Denmark.
It is currently debated whether the mechanism of action of therapeutic doses of recombinant factor VIIa (rFVIIa, Novo-Seven) relies on the tissue factor (TF)-independent activity of the enzyme. The present study was conducted to investigate the in vivo hemostatic effects of rFVIIa and 3 analogs thereof with superior intrinsic activity (FVIIaIIa, K337A-FVIIaIia, and M298Q-FVIIa) in mice with antibody-induced hemophilia A. A highly significant dose response was observed for the bleeding time and blood loss for each of the rFVIIa variants. The bleeding time and blood loss were normalized after administration of 10 mg/kg rFVIIa, 3 mg/kg K337A-FVIIaIia, and 3 mg/kg M298Q-FVIIa, indicating a potency of these FVIIa analogs 3-4 times above that of rFVIIa in FVIII-depleted mice. The different in vivo potencies of the various forms of FVIIa could not be explained by the pharmacokinetics. Histopathological evaluation of kidneys revealed no signs of treatment-related pathological changes even after treatment with the superactive variants. The fact that FVIIa analogs with enhanced intrinsic activity are more efficacious in the murine hemophilia A model strongly suggests that the TF-independent procoagulant activity of FVIIa contributes to its clinical hemostatic effect. (Blood. 2003; 102:3615-3620)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Margaritis, E. Roy, M. N. Aljamali, H. D. Downey, U. Giger, S. Zhou, E. Merricks, A. Dillow, M. Ezban, T. C. Nichols, et al.
Successful treatment of canine hemophilia by continuous expression of canine FVIIa
Blood,
April 16, 2009;
113(16):
3682 - 3689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hoffman
FVIIa: you've come a long way, baby!
Blood,
October 15, 2008;
112(8):
3002 - 3003.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Weeterings, P. G. de Groot, J. Adelmeijer, and T. Lisman
The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface
Blood,
October 15, 2008;
112(8):
3227 - 3233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Mannucci and M. Levi
Prevention and Treatment of Major Blood Loss
N. Engl. J. Med.,
May 31, 2007;
356(22):
2301 - 2311.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Allen, E. Persson, R. A. Campbell, M. Ezban, U. Hedner, and A. S. Wolberg
A Variant of Recombinant Factor VIIa With Enhanced Procoagulant and Antifibrinolytic Activities in an In Vitro Model of Hemophilia
Arterioscler Thromb Vasc Biol,
March 1, 2007;
27(3):
683 - 689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. B. Johansen, M. Tranholm, and M. Ezban
Safety Aspects of NN1731, a New Variant of Recombinant Factor VIIa with Increased Intrinsic Activity, in a Venous Stasis Model in Rabbits.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
1758 - 1758.
[Abstract]
[PDF]
|
|
|
|
|
|
|
X. Huang, W.-Q. Ding, J. L. Vaught, R. F. Wolf, J. H. Morrissey, R. G. Harrison, and S. E. Lind
A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties
Blood,
February 1, 2006;
107(3):
980 - 986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-Y. Jin, T.-P. Zhang, T. Gui, D. W. Stafford, and P. E. Monahan
Creation of a mouse expressing defective human factor IX
Blood,
September 15, 2004;
104(6):
1733 - 1739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
